Evidence-Based Complementary and Alternative Medicine / 2019 / Article / Tab 1 / Research Article
Randomized, Double-Blinded, Multicenter, Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome) Table 1 Comparison of demographic and baseline clinical characteristics of participants between the SFI and placebo groups.
Characteristic SFI Placebo Statistics P value Basic information Age ( , yrs) 68.58±8.42 68.14±8.73 -0.3042 0.7610 Gender Male n(%) 42(56.76%) 48(68.57%) 2.1424 0.1433 Female n(%) 32(43.24%) 22(31.43%) Weight ( , kg) 65.43±13.10 66.26±11.82 0.5744 0.5657 Height ( , cm) 164.10±7.30 166.00±6.60 1.63 0.1052 SBP ( , mmHg) 132.55±21.89 133.27±19.47 0.2648 0.7912 DBP ( , mmHg) 77.26±10.77 77.64±11.04 0.3134 0.7540 Heart rate ( , bpm) 86.5±21.6★ 76.1±20.0 -3.1526 0.0016 Medical history Disease course of CHF ( , yrs) 4.62±6.07 3.76±3.69 -0.4280 0.6687 Disease course of acute exacerbation ( , days) 6.08±5.07 6.94±8.27 0.1853 0.8530 History of myocardial infarction n(%) 38(52.05%) 43(61.43%) 1.2785 0.2582 History of arrhythmia n(%) 20(27.03%) 19(27.14%) 0.0002 0.9875 History of hypertension n(%) 51(70.83%) 44(62.86%) 1.0197 0.3126 History of diabetes n(%) 26(35.14%) 16(22.86%) 2.6248 0.1052 Medication use Antiplatelet n(%) 63 (85.14%) 61 (87.14%) 0.1212 0.7277 Beta-blockers n(%) 36 (48.65%) 44 (62.86%) 2.9412 0.0863 ACE inhibitors n(%) 32 (43.24%) 35 (50.00%) 0.6601 0.4165 ARB inhibitors n(%) 23 (31.08%) 19 (27.14%) 0.2700 0.6033 Statins n(%) 57 (77.03%) 50 (71.43%) 0.5905 0.4422 Nitric acid lipid n(%) 44 (59.46%) 44 (62.86%) 0.1747 0.6759 Ca-antagonist n(%) 18 (24.32%) 17 (24.29%) 0.0000 0.9957 Aldosterone receptor antagonist n(%) 50 (67.57%) 43 (61.43%) 0.5927 0.4414 Diuretics n(%) 45 (60.81%) 35 (50.00%) 1.7027 0.1919 Digoxin n(%) 29 (39.19%) 24 (34.29%) 0.3719 0.5420 Clinical index TCM syndrome score ( ) 24.54±7.90 23.37±7.13 -1.1902 0.2340 Lee’s heart failure ( ) 6.36±3.25 5.71±2.92 -1.1787 0.2385 6MWD ( , m) 163.28±153.48 185.70±143.30 1.0504 0.2935 LVEF ( , %) 38.69±8.52 39.82±8.04 0.7183 0.4726 NYHA classification III n(%) 46(62.16%) 51(72.86%) 1.8715 0.1713 IV n(%) 28(37.84%) 19(27.14%)
★ P<0.01 compared to control group